Injectable contraception - New and existing options

被引:51
|
作者
Kaunitz, AM [1 ]
机构
[1] Univ Florida, Hlth Sci Ctr, Dept Obstet & Gynecol, Jacksonville, FL 32209 USA
关键词
D O I
10.1016/S0889-8545(05)70171-6
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The 3-month injectable depomedroxyprogesterone acetate (DMPA) and the monthly injectable Lunelle (MPA/E2C) offer women safe, effective, and convenient reversible birth control choices. Patients using DMPA usually experience amenorrhea and a delayed return of fertility whereas patients using MPA/E2C generally have regular cycles and a rapid return of fertility. Lactating women and others in whom contraceptive doses of estrogen are contraindicated can use progestin-only DMPA. For women who dislike daily pill taking, prefer regular cycles to amenorrhea, find monthly injections acceptable, and prefer a short-acting contraceptive, MPA/E2C is appealing. The more innovations clinicians, family planning agencies, and insurers can make to facilitate access to care (including reinjections), the more women will choose to use these reversible methods of contraception.
引用
收藏
页码:741 / +
页数:41
相关论文
共 50 条
  • [41] The Coming-of-Age of Subcutaneous Injectable Contraception
    Cole, Kimberly
    Saad, Abdulmumin
    GLOBAL HEALTH-SCIENCE AND PRACTICE, 2018, 6 (01): : 1 - 5
  • [42] INJECTABLE CONTRACEPTION (MEDROXYPROGESTERONE ACETATE) IN RURAL BANGLADESH
    PARVEEN, L
    CHOWDHURY, AQ
    CHOWDHURY, Z
    LANCET, 1977, 2 (8045): : 946 - 948
  • [43] Injectable Contraception: Current Practices and Future Trends
    Kristen Wolfe
    Catherine Cansino
    Current Obstetrics and Gynecology Reports, 2015, 4 (1) : 26 - 36
  • [44] Update on permanent contraception options for women
    Patil, Eva
    Jensen, Jeffrey T.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2015, 27 (06) : 465 - 470
  • [45] Emergency contraception: Oral and intrauterine options
    Black, Kirsten I.
    Hussainy, Safeera Y.
    AUSTRALIAN FAMILY PHYSICIAN, 2017, 46 (10) : 722 - 726
  • [46] Expanding Treatment Options for Injectable Agents
    Goldberg, David J.
    Bass, Lawrence M.
    Fitzgerald, Rebecca
    Graivier, Miles H.
    Lorenc, Z. Paul
    AESTHETIC SURGERY JOURNAL, 2018, 38 : S1 - S7
  • [47] Engaging With Program Adaptations in Evaluation: A Range of Existing Options and a New Opportunity
    Mark, Melvin M.
    AMERICAN JOURNAL OF EVALUATION, 2022, 43 (03) : 314 - 334
  • [48] Injectable contraception: what should the longest interval be for reinjections?
    Steiner, Markus J.
    Kwok, Cynthia
    Stanback, John
    Byamugisha, Josaphat K.
    Chipato, Tsungai
    Magwali, Thulani
    Mmiro, Francis
    Rugpao, Sungwal
    Sriplienchan, Somchai
    Morrison, Charles
    CONTRACEPTION, 2008, 77 (06) : 410 - 414
  • [49] ESTROGENIC ACTIVITY IN WOMEN RECEIVING AN INJECTABLE PROGESTOGEN FOR CONTRACEPTION
    MISHELL, DR
    THORNEYCROFT, IH
    NAKAMURA, RM
    KHARMA, KM
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1972, 113 (03) : 372 - +
  • [50] Contraception 2000:: Lunelle™, an injectable combination contraceptive option
    Shulman, LP
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2000, 9 (07): : 725 - 729